{"id":"as-50-eye-drops-8-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or stinging"},{"rate":null,"effect":"Temporary blurred vision"},{"rate":null,"effect":"Hyperemia (redness)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sodium chloride (hypertonic saline) at 50% concentration creates an osmotic gradient across the corneal epithelium, reducing corneal swelling and improving transparency. This mechanism is used to temporarily improve vision in patients with corneal edema and to facilitate corneal examination. The effect is reversible and symptomatic rather than curative.","oneSentence":"AS 50% eye drops provide osmotic dehydration of corneal edema by drawing fluid from the cornea into the anterior chamber.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:26:26.953Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Corneal edema (bullous keratopathy)"},{"name":"Temporary improvement of vision in corneal edema"}]},"trialDetails":[{"nctId":"NCT02434328","phase":"PHASE3","title":"Efficacy and Safety of RTH258 Versus Aflibercept - Study 2","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2015-07-28","conditions":"Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":1048},{"nctId":"NCT02307682","phase":"PHASE3","title":"Efficacy and Safety of RTH258 Versus Aflibercept - Study 1","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2014-12-08","conditions":"Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":1775},{"nctId":"NCT01873131","phase":"NA","title":"A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2011-02","conditions":"Hemangioma","enrollment":126},{"nctId":"NCT04683796","phase":"PHASE3","title":"Comparison of Efficacy Between 100% Platelet-rich Plasma and 100% Serum Eye Drops in Dry Eye Disease","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2021-02-01","conditions":"Dry Eye Disease","enrollment":96},{"nctId":"NCT03666884","phase":"PHASE4","title":"The Comparison of 50% AS Versus PFAT+ 0.05 % COE in Severe Dry Eye Syndrome","status":"COMPLETED","sponsor":"Seref istek","startDate":"2015-10-10","conditions":"Dry Eye Syndrome","enrollment":36},{"nctId":"NCT00109837","phase":"PHASE2","title":"S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2005-04","conditions":"Leukemia","enrollment":79}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["50% autologous serum eye drops 8*1"],"phase":"marketed","status":"active","brandName":"AS 50% eye drops 8*1","genericName":"AS 50% eye drops 8*1","companyName":"Seref istek","companyId":"seref-istek","modality":"Biologic","firstApprovalDate":"","aiSummary":"AS 50% eye drops provide osmotic dehydration of corneal edema by drawing fluid from the cornea into the anterior chamber. Used for Corneal edema (bullous keratopathy), Temporary improvement of vision in corneal edema.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}